Jove
Visualize
Contact Us

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press.

British journal of pharmacology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World journal of urology·2025
Same author

A Comprehensive Review and Meta-analysis on the Treatment of Acute Gastroenteritis in Children with a Bacillus clausii Preparation (Enterogermina<sup>®</sup>).

Advances in therapy·2025
Same author

A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood.

Journal of clinical medicine·2025
Same journal

Endothelial Cell Phenotypic Plasticity in Atherosclerosis.

Handbook of experimental pharmacology·2026
Same journal

Endothelial Dysfunction and Neurovascular Alterations in Autism Spectrum Disorder.

Handbook of experimental pharmacology·2026
Same journal

Molecular Mechanisms of Endothelial Shear Stress Mechanotransduction in Health and Disease.

Handbook of experimental pharmacology·2026
Same journal

Microvasculature of the Pancreatic Islets of Langerhans in Health and Diabetes.

Handbook of experimental pharmacology·2026
Same journal

Mechanisms of Actions of Physiological, Pharmacological, and Toxicological Dietary Bioactive Inorganic Boron.

Handbook of experimental pharmacology·2026
Same journal

BNCT Plus Luminescence: New Paradigm for Boron-Containing Drug Design.

Handbook of experimental pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development Perspective.

Martin C Michel1, Ongun Onaran2

  • 1Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. marmiche@uni-mainz.de.

Handbook of Experimental Pharmacology
|September 13, 2025
PubMed
Summary
This summary is machine-generated.

Achieving drug selectivity is crucial for minimizing side effects. Biased agonism offers potential for functional target selectivity, but its application in drug development remains complex and challenging.

Keywords:
Biased agonismDrug developmentβ1-adrenoceptorβ2-adrenoceptorβ3-adrenoceptor

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of &#946;2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.3K

Related Experiment Videos

Last Updated: Jan 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of &#946;2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.3K

Area of Science:

  • Pharmacology
  • Drug Development
  • Molecular Biology

Background:

  • Drug selectivity aims to maximize desired therapeutic effects while minimizing adverse side effects.
  • Traditional selectivity strategies include target specificity, pharmacokinetics, and differential tissue efficacy.
  • Biased agonism, where a ligand preferentially activates one signaling pathway over others, presents a more nuanced approach.

Purpose of the Study:

  • To explore the concept and challenges of biased agonism in drug development.
  • To understand the role of biased agonism in achieving functional target selectivity.
  • To assess the complexities in identifying and utilizing biased ligand profiles for therapeutic benefit.

Main Methods:

  • Review of existing literature on biased agonism and drug selectivity.
  • Analysis of the complexities in assessing ligand bias, particularly for beta-adrenoceptors.
  • Discussion of challenges in determining desired biased profiles early in drug research.

Main Results:

  • Biased agonism is a complex phenomenon that is difficult to assess accurately.
  • Beta-adrenoceptors serve as a key model for studying biased agonism, but findings are often inconclusive.
  • Current methods for assessing biased signaling present significant challenges for drug development.

Conclusions:

  • Biased agonism holds promise for enhancing functional target selectivity in drug design.
  • Significant complexities in assessment hinder the prospective use of biased agonism in drug discovery.
  • Further research is needed to overcome these challenges and leverage biased agonism effectively.